XIIDRA IS A FIRST-IN-CLASS
RX THERAPY THOUGHT
TO TARGET BOTH ACTIVE
AND INACTIVE T CELLS1-4

XIIDRA IS
A FIRST-IN-CLASS
RX THERAPY THOUGHT
TO TARGET BOTH
ACTIVE AND
INACTIVE T CELLS1-4

Xiidra is a nonsteroid therapy that can disrupt
inflammation at an important source1,3-5

It was specifically designed to target a source of underlying
inflammation that may fuel dry eye disease (DED)1,3-5

Xiidra is a nonsteroid therapy that can
disrupt inflammation at an important source1,3-5

It was specifically designed to target a source
of underlying inflammation that may
fuel dry eye disease (DED)1,3-5

Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in DED and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release.1,3,4

The exact mechanism of action of Xiidra in DED is not known.1

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Click here for Full Prescribing Information.

References

  1. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020.

  2. US Food and Drug Administration. FDA approves new medication
    for dry eye disease. Published July 12, 2016. Accessed April 30, 2021.
    https://www.fda.gov/news-events/press-announcements/
    fda-approves-new-medication-dry-eye-disease

  3. Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207-215.

  4. Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33(1):5-12.

  5. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II Pathophysiology Report. Ocul Surf. 2017;15(3):438-510.